Amarin Corporation PLC (AMRN) News & EventsAMRNAmarin Corporation PLC

Volkswagen to Invest $4B in Georgia Plant

Get caught up quickly on the top news from the weekend this five Top Five list.Volkswagen'sAudi announced plans to establish its first U.S. production site in Georgia. The company intends to invest around $4B and create approximately 4,500 jobs. Construction of the plant, designed for an annual production capacity of up to 200,000 vehicles, is scheduled to begin in 2027, with production planned to start in the early 2030s.Bon Secours Mercy Health is in late-stage discussions to purchase a majority stake inSurgery Partners, which would value the group at $20 a share, Oliver Barnes of The Financial Times reports, citing people familiar with the matter. Bain Capital, which has been a minority shareholder in the company since 2017, will retain a 40% holding in Surgery Partners. The potential deal could be announced as soon as Monday.Genentech, a member of theRoche Group,announced results from the Phase III Krascendo 1 study, which demonstrated the "superior efficacy" of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer, NSCLC. The study met primary and key secondary endpoints, and divarasib demonstrated statistically significant and clinically meaningful improvements in OS and progression-free survival over sotorasib or adagrasib.Amarinhighlighted findings from the EPA for Metastasis Trial 2, EMT2, a randomized, double-blind, placebo-controlled, multi-center, Phase 3 investigator-initiated trial sponsored by the University of Leeds and presented as a late breaker at the European Society for Medical Oncolog 2026 Congress in Madrid, Spain. The presented results showed the trial did not meet its pre-specified primary endpoint of progression-free survival in the intent-to-treat population: median PFS was 13.5 months with IPE versus 12.9 months with placebo. However, the pre-specified key secondary endpoint of overall survival demonstrated a statistically significant benefit in the ITT population.Akesoannounced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase III HARMONi-GI1 trial. The study evaluated first-in-class ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for patients with advanced biliary tract cancer and was presented at the 2026 European Society for Medical Oncology Congress in Madrid, Spain. In a prespecified interim analysis reviewed by the Independent Data Monitoring Committee, HARMONi-GI1 met its primary endpoint of overall survival, OS, with the ivonescimab plus chemotherapy arm demonstrating statistically significant and clinically meaningful improvement over the control arm. The trial also met all key secondary endpoints, including progression-free survival, PFS, and objective response rate, ORR.

Amarin Reports EMT2 Trial Results, Misses Primary Endpoint

Amarin highlighted findings from the EPA for Metastasis Trial 2, EMT2, a randomized, double-blind, placebo-controlled, multi-center, Phase 3 investigator-initiated trial sponsored by the University of Leeds and presented as a late breaker at the European Society for Medical Oncolog 2026 Congress in Madrid, Spain. The research presented by the Chief Investigator, Professor Mark Hull, added to the scientific understanding of VAZKEPA/VASCEPA. The presented results showed the trial did not meet its pre-specified primary endpoint of progression-free survival in the intent-to-treat population: median PFS was 13.5 months with IPE versus 12.9 months with placebo. However, the pre-specified key secondary endpoint of overall survival demonstrated a statistically significant benefit in the ITT population.

Amarin Celebrates New Guidelines Including CV Risk Treatment for Hypertriglyceridemia Patients

Amarin celebrated the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology, or ACC, / American Heart Association, or AHA,/Multisociety Dyslipidemia Guideline Update. These newly-issued, evidenced-based recommendations summarize the clinical role of icosapent ethyl in reducing cardiovascular, or CV, risk in statin-treated patients with elevated triglycerides, or TG, and fully align with Amarin's commitment to addressing the burden of CV disease across the healthcare ecosystem. The updated guideline reinforces that patients on statin therapy can experience residual CV risk driven by elevated TG levels - a significant clinical challenge affecting millions of Americans. Amarin's VASCEPA/VAZKEPA, or icosapent ethyl, is an effective, safe, oral therapy that has been prescribed more than 30M times globally.